The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, ...
During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies ...
The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
Number 3: Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while ...
A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% ...
A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...
A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment ...
Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex ...
Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona Cancer Center, discusses the potential of biosimilars and challenges in the ...
On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...
The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback